Denali Therapeutics | Company Profile
Contact Information
Industry & Market
Company Metrics
Funding Information
Headcount Distribution
By Department
Department Breakdown
Technology Stack
Analytics & Tracking
Video & Media
Email & Communication
Keywords & Focus Areas
Denali Therapeutics
Overview
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company is dedicated to discovering and developing therapies for neurodegenerative and lysosomal storage diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Denali leverages scientific insights into the genetic and biological mechanisms of these conditions to create effective treatments.
The company specializes in engineering therapies that can cross the blood-brain barrier, a key challenge in treating brain diseases. Its portfolio includes several drug candidates, such as DNL310 for Hunter syndrome, DNL151 for Parkinson's disease, and DNL919 for Alzheimer's disease. Denali collaborates with major pharmaceutical companies to enhance drug development efforts and is committed to improving patient outcomes through rigorous research and innovative delivery technologies.
Basic Information
| Industry | research |
|---|---|
| Founded | 2015 |
| Revenue | 330.5M |
| Headquarters | 161 Oyster Point Blvd, South San Francisco, California 94080, United States |
| Languages | English |
Contact Details
- Phone: +1 650-866-8548
- Website: denalitherapeutics.com
- LinkedIn: linkedin.com/company/denali-therapeutics
Key Focus Areas & Initiatives
- Biotechnology research
- Discovering and developing therapies for neurodegenerative diseases
- Lysosomal storage disease therapeutics
- Engineering therapies to cross the blood-brain barrier
- Drug candidates: DNL310, DNL151, DNL919
- Partnerships and collaborations with pharmaceutical companies
- Clinical trial development
- Biomarker-driven research
- Patient-focused outcomes improvement
- Innovative drug delivery platforms
- Translational medicine and genetic validation
- Therapeutics for rare diseases (e.g., MPS II, MPS IIIA)
- Neuroscience research and clinical pipeline expansion
Technologies Used
- Amazon AWS
- Circle
- CloudFlare Hosting
- Drupal
- Gmail
- Google Analytics
- Google Apps
- Google Tag Manager
- Greenhouse.io
- MailChimp SPF
- Microsoft Office 365
- Mobile Friendly
- New Relic
- Outlook
- React
- Remote
- Salesforce
- Segment.io
- Sigma
- Typekit
- YouTube
Community
